Skip to main content

Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)

Agency: National Institutes of Health

Assistance Listings
  • 93.350 -- National Center for Advancing Translational Sciences

Forecasted opportunityLast Updated: May 13, 2026

Important dates

  • Forecasted post date: October 15, 2025
  • Forecasted application due date: February 17, 2026
  • Forecasted award date: December 17, 2026
  • Forecasted project start date: January 18, 2027
  • Fiscal Year: 2027

Award details

  • Expected project funding: Not specified
  • Expected awards: Not specified

Award min.

Not specified

Award max.

Not specified

  • Funding opportunity number:FOR-TR-27-002
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Cooperative agreement
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Health
  • Category Explanation:Not specified

History

  • Forecast posted date: June 27, 2025
  • Archive date: Not specified
  • Version: 1

View version history on Grants.gov

Summary

The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine.


The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe), is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration.


Areas of interest for ExTReMe could include, but are not limited to:

  1. direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies);
  2. designer EVs (personalized to the individual patient’s needs).


Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network

Eligibility

Nonprofit

  • Other Native American tribal organizations
  • Nonprofits non-higher education with 501(c)(3)

Education

  • Public and state institutions of higher education
  • Private institutions of higher education
  • Independent school districts

Government

  • Federally recognized Native American tribal governments
  • State governments
  • Public and Indian housing authorities
  • County governments

Business

  • Small businesses
  • For-profit organizations other than small businesses

Additional information on eligibility

Not specified

Documents

No documents are currently available.

Agency contact information

Email: christine.happel@nih.gov

christine.happel@nih.gov

Christine Happel, Ph.D. National Center for Advancing Translational Sciences (NCATS) 240-472-7550

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov